A multicentre, randomised, double-blind, placebo-controlled, Phase 2 study comparing 3mg and 12mg of LY3202626 with placebo over 52 weeks in approximately 500 patients with mild Alzheimer’s disease dementia (NAVIGATE-AD).
DEMENTIA TRIALS AUSTRALIA
A multicentre, randomised, double-blind, placebo-controlled, Phase 2 study comparing 3mg and 12mg of LY3202626 with placebo over 52 weeks in approximately 500 patients with mild Alzheimer’s disease dementia (NAVIGATE-AD).